



Dr. Steven Theriault
Cytophage Technologies Inc.
26 Henlow Bay
Winnipeg, MB R3Y 1G4
CANADA

Re: GRAS Notice No. GRN 001163

Dear Dr. Theriault:

The Food and Drug Administration (FDA, we) is granting the request to cease our evaluation of GRN 001163, which we filed on January 4, 2024. We received this request on May 17, 2024.

The subject of the notice is a preparation containing two bacteriophages (phage) specific to *Salmonella enterica* (*Salmonella* phage preparation) for use as an antimicrobial on the surface of raw poultry at levels up to 2×10^8 plaque forming units (PFU)/g of food. The notice informs us of Cytophage's view that this use of *Salmonella* phage preparation is GRAS through scientific procedures.

In an email dated March 14, 2024, we provided you with a list of questions raised during our evaluation of GRN 001163. In an email dated May 17, 2024, you requested that we cease our evaluation of GRN 001163 because you will be making a change to your manufacturing process to address our questions.

In accordance with 21 CFR 170.275(b)(3), the text of this letter responding to GRN 001163 is accessible to the public at www.fda.gov/grasnoticeinventory.

Sincerely,

Susan J. Carlson - Digitally signed by Susan J.
Carlson -S
Date: 2024.05.28 11:52:02 -04'00'

S
Susan J. Carlson, Ph.D.
Director
Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety
and Applied Nutrition

U.S. Food and Drug Administration
Center for Food Safety & Applied Nutrition
5001 Campus Drive
College Park, MD 20740
www.fda.gov

Page 2 – Dr. Theriault

cc: Stephanie Hretz, M.P.H.
Director
USDA/FSIS/OPPD/RIMS
1400 Independence Ave. SW
Washington, DC 20250-3700